Alpha Cognition (NASDAQ:ACOG) Releases Earnings Results, Misses Estimates By $0.01 EPS

Alpha Cognition (NASDAQ:ACOG) released its earnings results on Thursday. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.01), Zacks reports. Alpha Cognition had a negative net margin of 232.23% and a negative return on equity of 58.35%.

Here are the key takeaways from Alpha Cognition’s conference call:

• ZUNVEYL net product revenue rose 71% sequentially to approximately $6 million in Q2 2026, with demand increasing each month and June marking the strongest month to date.
• Commercial adoption continued to deepen, with 1,347 active prescribers, 1,095 nursing homes placing prescriptions, and repeat utilization from approximately 76% of writers and 81% of prescribing homes.
• Management highlighted positive BEACON findings across cognition, neuropsychiatric symptoms, activities of daily living, and polypharmacy, while CONVERGE data is expected in Q3 2026 and RESOLVE remains on track to complete in Q2 2027.
• Payer and formulary expansion remains the largest near-term constraint; broad activation has been slower than expected, with coverage holding at roughly 74% and no significant formulary wins reported in Q2.
• The company reduced 2026 operating-expense guidance to $50 million-$54 million from $54 million-$58 million, ended Q2 with $41.4 million in cash, and reiterated its target of reaching operating profitability in 2027.

Alpha Cognition Stock Performance

Shares of NASDAQ ACOG traded down $0.32 during mid-day trading on Thursday, hitting $8.63. The stock had a trading volume of 200,919 shares, compared to its average volume of 64,023. The firm has a market cap of $187.88 million, a P/E ratio of -6.39 and a beta of 2.31. The business has a 50 day moving average price of $7.63 and a two-hundred day moving average price of $6.49. Alpha Cognition has a 1 year low of $4.50 and a 1 year high of $10.00.

Analyst Ratings Changes

A number of brokerages have recently weighed in on ACOG. Wall Street Zen lowered Alpha Cognition from a “hold” rating to a “sell” rating in a research report on Saturday, May 2nd. Maxim Group initiated coverage on Alpha Cognition in a research report on Friday, May 29th. They issued a “buy” rating and a $12.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price objective on shares of Alpha Cognition in a research report on Friday, May 22nd. Craig Hallum assumed coverage on Alpha Cognition in a research note on Friday, April 17th. They issued a “buy” rating and a $14.00 target price on the stock. Finally, Raymond James Financial began coverage on shares of Alpha Cognition in a research note on Friday, July 10th. They set an “outperform” rating and a $20.00 price target on the stock. Four equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Alpha Cognition has an average rating of “Buy” and an average target price of $16.00.

Institutional Investors Weigh In On Alpha Cognition

A number of large investors have recently modified their holdings of ACOG. Geode Capital Management LLC purchased a new stake in Alpha Cognition in the second quarter worth about $112,000. Massar Capital Management LP bought a new position in shares of Alpha Cognition in the second quarter worth approximately $116,000. Two Sigma Investments LP purchased a new stake in shares of Alpha Cognition during the third quarter valued at approximately $148,000. Connective Capital Management LLC bought a new stake in shares of Alpha Cognition during the third quarter valued at approximately $312,000. Finally, Marshall Wace LLP bought a new stake in shares of Alpha Cognition during the second quarter valued at approximately $600,000.

Alpha Cognition Company Profile

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.